Experimental therapy for deadly brain tumor stalls after single patient

NCT ID NCT02742883

Terminated Disease control Sponsor: Burzynski Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 study tests two experimental drugs, atengenal and astugenal, in people with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. The trial aimed to enroll up to 100 participants across five age and treatment groups, but only 1 person joined before the study was suspended. The goal was to see if the drugs could shrink tumors or extend survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Antineoplaston therapy (atengenal and astugenal)
What this could lead to: If it works, this could point toward a treatment for DIPG, a rare and aggressive brain tumor in children.
What could go wrong: The trial is very early (phase 2), has only 1 participant, and is currently suspended. Antineoplaston therapy is controversial and not widely accepted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse intrinsic pontine glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE INTRINSIC PONTINE GLIOMA

Contacts and locations

Locations

Burzynski Clinic

Houston, Texas, 77055-6330, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.